Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 3
1989 6
1990 1
1991 5
1992 6
1993 3
1994 1
1995 4
1996 1
1997 5
1998 11
1999 7
2000 10
2001 7
2002 4
2003 8
2004 9
2005 10
2006 9
2007 15
2008 10
2009 13
2010 9
2011 12
2012 19
2013 29
2014 56
2015 40
2016 42
2017 62
2018 58
2019 62
2020 89
2021 98
2022 82
2023 107
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

840 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for sinai lv
Your search for Sicai Lv retrieved no results
Aortic Regurgitation.
Flint N, Wunderlich NC, Shmueli H, Ben-Zekry S, Siegel RJ, Beigel R. Flint N, et al. Curr Cardiol Rep. 2019 Jun 3;21(7):65. doi: 10.1007/s11886-019-1144-6. Curr Cardiol Rep. 2019. PMID: 31161305 Review.
Echocardiography is key for imaging the aortic valve morphology and flow as well as aortic root and ascending aorta. Determining LV ejection fraction and dimensions is essential for patient management and optimizing timing for intervention. ...Surgical or percutaneous ther …
Echocardiography is key for imaging the aortic valve morphology and flow as well as aortic root and ascending aorta. Determining LV e …
Left Ventricular Thrombus Following Acute Myocardial Infarction: JACC State-of-the-Art Review.
Camaj A, Fuster V, Giustino G, Bienstock SW, Sternheim D, Mehran R, Dangas GD, Kini A, Sharma SK, Halperin J, Dweck MR, Goldman ME. Camaj A, et al. J Am Coll Cardiol. 2022 Mar 15;79(10):1010-1022. doi: 10.1016/j.jacc.2022.01.011. J Am Coll Cardiol. 2022. PMID: 35272796 Free article. Review.
The incidence of left ventricular (LV) thrombus following acute myocardial infarction has markedly declined in recent decades caused by advancements in reperfusion and antithrombotic therapies. Despite this, embolic events remain the most feared complication of LV t …
The incidence of left ventricular (LV) thrombus following acute myocardial infarction has markedly declined in recent decades caused …
Pathophysiology and Echocardiographic Diagnosis of Left Ventricular Diastolic Dysfunction.
Silbiger JJ. Silbiger JJ. J Am Soc Echocardiogr. 2019 Feb;32(2):216-232.e2. doi: 10.1016/j.echo.2018.11.011. J Am Soc Echocardiogr. 2019. PMID: 30717860 Review.
Echocardiography is the primary imaging modality used for the clinical evaluation of left ventricular (LV) diastolic function. Using two-dimensional together with transmitral, mitral annular, and pulmonary venous Doppler data, conclusions may be drawn regarding the relaxat …
Echocardiography is the primary imaging modality used for the clinical evaluation of left ventricular (LV) diastolic function. Using …
Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images.
Sangha V, Nargesi AA, Dhingra LS, Khunte A, Mortazavi BJ, Ribeiro AH, Banina E, Adeola O, Garg N, Brandt CA, Miller EJ, Ribeiro ALP, Velazquez EJ, Giatti L, Barreto SM, Foppa M, Yuan N, Ouyang D, Krumholz HM, Khera R. Sangha V, et al. Circulation. 2023 Aug 29;148(9):765-777. doi: 10.1161/CIRCULATIONAHA.122.062646. Epub 2023 Jul 25. Circulation. 2023. PMID: 37489538 Free PMC article.
The use of ECG signals in screening for LV systolic dysfunction is limited by their availability to clinicians. ...An ECG suggestive of LV systolic dysfunction portended >27-fold higher odds of LV systolic dysfunction on transthoracic echocardiogram (odds …
The use of ECG signals in screening for LV systolic dysfunction is limited by their availability to clinicians. ...An ECG suggestive …
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ; EMPA-TROPISM (ATRU-4) Investigators. Santos-Gallego CG, et al. J Am Coll Cardiol. 2021 Jan 26;77(3):243-255. doi: 10.1016/j.jacc.2020.11.008. Epub 2020 Nov 13. J Am Coll Cardiol. 2021. PMID: 33197559 Free article. Clinical Trial.

Empagliflozin was associated with reductions in LV mass (-17.8 31.9 g vs. 4.1 13.4 g, for empagliflozin vs. placebo, respectively; p < 0.001) and LV sphericity, and improvements in LV ejection fraction (6.0 4.2 vs. -0.1 3.9; p < 0.001). ...CONCLUSIONS:

…
Empagliflozin was associated with reductions in LV mass (-17.8 31.9 g vs. 4.1 13.4 g, for empagliflozin vs. placebo, respectively; p …
The Transition From Hypertension to Heart Failure: Contemporary Update.
Messerli FH, Rimoldi SF, Bangalore S. Messerli FH, et al. JACC Heart Fail. 2017 Aug;5(8):543-551. doi: 10.1016/j.jchf.2017.04.012. Epub 2017 Jul 12. JACC Heart Fail. 2017. PMID: 28711447 Free article. Review.
Cardiac remodeling to a predominant pressure overload consists of diastolic dysfunction and concentric left ventricular (LV) hypertrophy. When pressure overload is sustained, diastolic dysfunction progresses, filling of the concentric remodeled LV decreases, and HF …
Cardiac remodeling to a predominant pressure overload consists of diastolic dysfunction and concentric left ventricular (LV) hypertro …
A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study.
Tu T, Toma C, Tapson VF, Adams C, Jaber WA, Silver M, Khandhar S, Amin R, Weinberg M, Engelhardt T, Hunter M, Holmes D, Hoots G, Hamdalla H, Maholic RL, Lilly SM, Ouriel K, Rosenfield K; FLARE Investigators. Tu T, et al. JACC Cardiovasc Interv. 2019 May 13;12(9):859-869. doi: 10.1016/j.jcin.2018.12.022. JACC Cardiovasc Interv. 2019. PMID: 31072507 Free article. Clinical Trial.
METHODS: Patients with symptomatic, computed tomography-documented PE and RV/left ventricular (LV) ratios 0.9 were eligible for enrollment. The primary effectiveness endpoint was core laboratory-assessed change in RV/LV ratio. ...Forty-three patients (41.3%) did not …
METHODS: Patients with symptomatic, computed tomography-documented PE and RV/left ventricular (LV) ratios 0.9 were eligible for enrol …
Assessing LV remodeling in nuclear cardiology.
Germano G, Slomka PJ. Germano G, et al. J Nucl Cardiol. 2019 Feb;26(1):233-235. doi: 10.1007/s12350-017-0957-1. Epub 2017 Jun 14. J Nucl Cardiol. 2019. PMID: 28616800 No abstract available.
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ. Santos-Gallego CG, et al. J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056. J Am Coll Cardiol. 2019. PMID: 30999996 Free article.
RESULTS: Despite similar initial ischemic myocardial injury in both groups, the empagliflozin group showed amelioration of adverse remodeling at 2 months (lower left ventricular [LV] mass, reduced LV dilatation, less LV sphericity) versus the control group. …
RESULTS: Despite similar initial ischemic myocardial injury in both groups, the empagliflozin group showed amelioration of adverse remodelin …
840 results